Carcinoma
MONDO:0004993A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.
Also known as: epithelioma, Other carcinoma, carcinoma, carcinoma, malignant, epithelial carcinoma, epithelioma malignant, malignant epithelial neoplasm, malignant epithelial tumor
16980 clinical trials for this condition and its sub-types, 224 tagged with Carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Carcinoma
-
Adenocarcinoma 186 trials · 5,262 incl. sub-types
64 sub-types
- Hepatocellular carcinoma 1,046 trials · 1,091 incl. sub-types Sub-types →
- Pancreatic adenocarcinoma 497 trials · 930 incl. sub-types Sub-types →
- Renal cell carcinoma 611 trials · 710 incl. sub-types Sub-types →
- Tubular adenocarcinoma 0 trials · 558 incl. sub-types Sub-types →
- Colorectal adenocarcinoma 247 trials · 548 incl. sub-types Sub-types →
- Gastroesophageal junction adenocarcinoma 507 trials
- Gastric adenocarcinoma 449 trials · 481 incl. sub-types Sub-types →
- Bile duct adenocarcinoma 17 trials · 419 incl. sub-types Sub-types →
- Prostate adenocarcinoma 298 trials Sub-types →
- Breast adenocarcinoma 36 trials · 279 incl. sub-types Sub-types →
- Serous adenocarcinoma 6 trials · 242 incl. sub-types Sub-types →
- Ovarian adenocarcinoma 12 trials · 231 incl. sub-types Sub-types →
- Clear cell adenocarcinoma 14 trials · 201 incl. sub-types Sub-types →
- Esophageal adenocarcinoma 170 trials · 174 incl. sub-types Sub-types →
- Adenocarcinoma in situ 10 trials · 170 incl. sub-types Sub-types →
- Endometrioid adenocarcinoma 13 trials · 146 incl. sub-types Sub-types →
- Endometrium adenocarcinoma 30 trials · 119 incl. sub-types Sub-types →
- Thyroid gland adenocarcinoma 0 trials · 118 incl. sub-types Sub-types →
- Lung adenocarcinoma 114 trials · 117 incl. sub-types Sub-types →
- Gastroesophageal adenocarcinoma 93 trials
- Papillary adenocarcinoma 2 trials · 93 incl. sub-types Sub-types →
- Fallopian tube adenocarcinoma 4 trials · 81 incl. sub-types Sub-types →
- Small intestine adenocarcinoma 18 trials · 60 incl. sub-types Sub-types →
- Mucinous adenocarcinoma 18 trials · 57 incl. sub-types Sub-types →
- Adenoid cystic carcinoma 47 trials · 48 incl. sub-types Sub-types →
- Cervical adenocarcinoma 27 trials · 34 incl. sub-types Sub-types →
- Poorly differentiated thyroid gland carcinoma 17 trials
- Acinar cell carcinoma 4 trials · 15 incl. sub-types Sub-types →
- Signet ring cell carcinoma 4 trials · 11 incl. sub-types Sub-types →
- Paget disease 2 trials · 9 incl. sub-types Sub-types →
- Gallbladder adenocarcinoma 9 trials Sub-types →
- Bladder adenocarcinoma 5 trials · 8 incl. sub-types Sub-types →
- Vaginal adenocarcinoma 7 trials Sub-types →
- Cystadenocarcinoma 0 trials · 6 incl. sub-types Sub-types →
- Diffuse type adenocarcinoma 1 trial · 6 incl. sub-types Sub-types →
- Vulvar adenocarcinoma 3 trials · 5 incl. sub-types Sub-types →
- Parathyroid gland carcinoma 4 trials
- Pituitary adenocarcinoma 3 trials Sub-types →
- Sebaceous adenocarcinoma 2 trials · 3 incl. sub-types Sub-types →
- Hepatoid adenocarcinoma 2 trials Sub-types →
- Mesonephric adenocarcinoma 2 trials Sub-types →
- Sweat gland carcinoma 1 trial · 2 incl. sub-types Sub-types →
- Urethra adenocarcinoma 1 trial · 2 incl. sub-types Sub-types →
- Follicular variant thyroid gland papillary carcinoma 1 trial
- Micropapillary serous carcinoma 1 trial
- Nasal cavity adenocarcinoma 1 trial
- Seminal vesicle adenocarcinoma 1 trial
- Trabecular adenocarcinoma 1 trial
- Ureter adenocarcinoma 1 trial
- Adenoacanthoma 0 trials
- Epididymal adenocarcinoma 0 trials
- Ethmoid sinus adenocarcinoma 0 trials
- Granular cell carcinoma 0 trials
- Intestinal type adenocarcinoma 0 trials Sub-types →
- Lacrimal gland adenocarcinoma 0 trials Sub-types →
- Maxillary sinus adenocarcinoma 0 trials
- Middle ear adenocarcinoma 0 trials
- Minor salivary gland adenocarcinoma 0 trials Sub-types →
- Rete testis adenocarcinoma 0 trials
- Salivary gland basal cell adenocarcinoma 0 trials
- Scirrhous adenocarcinoma 0 trials
- Submandibular gland adenocarcinoma 0 trials
- Thymus gland adenocarcinoma 0 trials Sub-types →
- Villous adenocarcinoma 0 trials Sub-types →
-
Digestive system carcinoma 25 trials · 4,898 incl. sub-types
16 sub-types
- Carcinoma of liver and intrahepatic biliary tract 36 trials · 1,461 incl. sub-types Sub-types →
- Colorectal carcinoma 305 trials · 1,170 incl. sub-types Sub-types →
- Exocrine pancreatic carcinoma 205 trials · 1,037 incl. sub-types Sub-types →
- Gastric carcinoma 92 trials · 555 incl. sub-types Sub-types →
- Carcinoma of esophagus 76 trials · 509 incl. sub-types Sub-types →
- Gastroesophageal junction adenocarcinoma 507 trials
- Carcinoma of pharynx 3 trials · 457 incl. sub-types Sub-types →
- Oral cavity carcinoma 16 trials · 202 incl. sub-types Sub-types →
- Small intestine carcinoma 19 trials · 105 incl. sub-types Sub-types →
- Gallbladder carcinoma 41 trials · 49 incl. sub-types Sub-types →
- Intestine carcinoma in situ 0 trials · 16 incl. sub-types Sub-types →
- Pancreatic endocrine carcinoma 12 trials Sub-types →
- Digestive system mixed adenoneuroendocrine carcinoma 0 trials · 3 incl. sub-types Sub-types →
- Carcinoma of floor of mouth 1 trial · 2 incl. sub-types Sub-types →
- Maxillary sinus carcinoma 1 trial · 2 incl. sub-types Sub-types →
- Ameloblastic carcinoma 0 trials
-
Lung carcinoma 137 trials · 3,325 incl. sub-types
10 sub-types
- Non-small cell lung carcinoma 2,725 trials · 2,839 incl. sub-types Sub-types →
- Small cell lung carcinoma 514 trials · 515 incl. sub-types Sub-types →
- Squamous cell lung carcinoma 66 trials · 146 incl. sub-types Sub-types →
- Bronchogenic carcinoma 25 trials Sub-types →
- Lung carcinoma in situ 2 trials · 3 incl. sub-types Sub-types →
- Combined lung carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Asbestos-related lung carcinoma 0 trials
- Lung epithelial-myoepithelial carcinoma 0 trials
- Lung hilum carcinoma 0 trials
- Lung inflammatory myofibroblastic tumor 0 trials
-
Breast carcinoma 665 trials · 2,693 incl. sub-types
13 sub-types
- Breast carcinoma by gene expression profile 0 trials · 1,791 incl. sub-types Sub-types →
- Invasive breast carcinoma 325 trials · 413 incl. sub-types Sub-types →
- Breast adenocarcinoma 36 trials · 279 incl. sub-types Sub-types →
- Breast carcinoma in situ 76 trials · 204 incl. sub-types Sub-types →
- Female breast carcinoma 138 trials Sub-types →
- Male breast carcinoma 22 trials
- Hereditary breast carcinoma 10 trials Sub-types →
- Bilateral breast carcinoma 6 trials · 9 incl. sub-types Sub-types →
- Hormone-resistant breast carcinoma 5 trials
- Sporadic breast cancer 2 trials
- Ehrlich tumor carcinoma 0 trials
- Cribriform carcinoma of breast 0 trials Sub-types →
- Nipple carcinoma 0 trials Sub-types →
-
Squamous cell carcinoma 177 trials · 1,774 incl. sub-types
39 sub-types
- Head and neck squamous cell carcinoma 831 trials · 1,057 incl. sub-types Sub-types →
- Esophageal squamous cell carcinoma 306 trials · 307 incl. sub-types Sub-types →
- Skin squamous cell carcinoma 151 trials · 158 incl. sub-types Sub-types →
- Squamous cell lung carcinoma 66 trials · 146 incl. sub-types Sub-types →
- Human papillomavirus-related squamous cell carcinoma 115 trials · 116 incl. sub-types Sub-types →
- Colorectal squamous cell carcinoma 1 trial · 54 incl. sub-types Sub-types →
- Adenosquamous carcinoma 8 trials · 45 incl. sub-types Sub-types →
- Cervical squamous cell carcinoma 36 trials · 40 incl. sub-types Sub-types →
- Metastatic squamous cell carcinoma 39 trials
- Squamous cell carcinoma of penis 21 trials · 29 incl. sub-types Sub-types →
- Vulvar squamous cell carcinoma 22 trials Sub-types →
- Squamous cell carcinoma of pancreas 3 trials · 13 incl. sub-types Sub-types →
- Bone squamous cell carcinoma 0 trials · 11 incl. sub-types Sub-types →
- Squamous carcinoma in situ 5 trials · 10 incl. sub-types Sub-types →
- Vaginal squamous cell carcinoma 8 trials
- Basaloid squamous cell carcinoma 2 trials · 5 incl. sub-types Sub-types →
- Bladder squamous cell carcinoma 5 trials Sub-types →
- Gastric squamous cell carcinoma 4 trials Sub-types →
- Papillary squamous carcinoma 1 trial · 4 incl. sub-types Sub-types →
- Thyroid gland squamous cell carcinoma 4 trials
- Endometrial squamous cell carcinoma 0 trials · 2 incl. sub-types Sub-types →
- Ovarian squamous cell carcinoma 2 trials
- Urethra squamous cell carcinoma 2 trials Sub-types →
- Keratinizing squamous cell carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Pure squamous carcinoma of the urothelial tract 1 trial
- Scrotum squamous cell carcinoma 1 trial
- Squamous cell carcinoma of the small intestine 1 trial Sub-types →
- Ureter squamous cell carcinoma 1 trial
- Fallopian tube squamous cell carcinoma 0 trials
- Gallbladder squamous cell carcinoma 0 trials Sub-types →
- Prostate squamous cell carcinoma 0 trials Sub-types →
- Pseudoglandular squamous cell carcinoma 0 trials
- Renal pelvis squamous cell carcinoma 0 trials
- Sarcomatoid squamous cell carcinoma 0 trials Sub-types →
- Squamous cell breast carcinoma 0 trials Sub-types →
- Squamous cell carcinoma of liver and intrahepatic biliary tract 0 trials Sub-types →
- Squamous cell carcinoma of the corpus uteri 0 trials
- Thymus squamous cell carcinoma 0 trials Sub-types →
- Trachea squamous cell carcinoma 0 trials Sub-types →
-
Head and neck carcinoma 74 trials · 1,420 incl. sub-types
16 sub-types
- Head and neck squamous cell carcinoma 831 trials · 1,057 incl. sub-types Sub-types →
- Lip and oral cavity carcinoma 96 trials · 260 incl. sub-types Sub-types →
- Oropharyngeal carcinoma 100 trials · 243 incl. sub-types Sub-types →
- Nasopharyngeal carcinoma 211 trials · 212 incl. sub-types Sub-types →
- Hypopharyngeal carcinoma 36 trials · 86 incl. sub-types Sub-types →
- Nasal cavity and paranasal sinus carcinoma 21 trials · 44 incl. sub-types Sub-types →
- Nasal cavity carcinoma 3 trials · 9 incl. sub-types Sub-types →
- Eye carcinoma 0 trials · 5 incl. sub-types Sub-types →
- Pituitary adenocarcinoma 3 trials Sub-types →
- Carcinoma of floor of mouth 1 trial · 2 incl. sub-types Sub-types →
- External ear carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Middle ear carcinoma 1 trial Sub-types →
- Ameloblastic carcinoma 0 trials
- Growth hormone-producing pituitary gland carcinoma 0 trials
- Laryngeal small cell carcinoma 0 trials
- Pharyngeal adenoid cystic carcinoma 0 trials
-
Prostate carcinoma 394 trials · 1,324 incl. sub-types
9 sub-types
- Metastatic prostate carcinoma 670 trials
- Castration-resistant prostate carcinoma 480 trials
- Prostate adenocarcinoma 298 trials Sub-types →
- Hormone-resistant prostate carcinoma 30 trials
- Prostate small cell carcinoma 9 trials
- Familial prostate carcinoma 0 trials
- Grade III prostatic intraepithelial neoplasia 0 trials
- Primary prostate urothelial carcinoma 0 trials Sub-types →
- Prostate squamous cell carcinoma 0 trials Sub-types →
-
Renal carcinoma 85 trials · 764 incl. sub-types
3 sub-types
- Renal cell carcinoma 611 trials · 710 incl. sub-types Sub-types →
- Renal pelvis carcinoma 15 trials · 22 incl. sub-types Sub-types →
- Kidney carcinoma in situ 0 trials Sub-types →
-
Neuroendocrine carcinoma 106 trials · 744 incl. sub-types
12 sub-types
- Small cell carcinoma 26 trials · 542 incl. sub-types Sub-types →
- Cutaneous neuroendocrine carcinoma 78 trials
- Medullary thyroid gland carcinoma 42 trials · 53 incl. sub-types Sub-types →
- Large cell neuroendocrine carcinoma 12 trials · 31 incl. sub-types Sub-types →
- Pancreatic endocrine carcinoma 12 trials Sub-types →
- Malignant adrenal gland pheochromocytoma 11 trials
- Liver neuroendocrine carcinoma 3 trials Sub-types →
- Thymic neuroendocrine carcinoma 3 trials Sub-types →
- Goblet cell carcinoma 2 trials
- Anal canal neuroendocrine neoplasm 1 trial Sub-types →
- Combined lung carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Vulvar neuroendocrine carcinoma 0 trials Sub-types →
-
Transitional cell carcinoma 250 trials · 724 incl. sub-types
9 sub-types
- Urothelial carcinoma 364 trials · 695 incl. sub-types Sub-types →
- Fallopian tube transitional cell carcinoma 12 trials
- Ovarian transitional cell carcinoma 12 trials
- Papillary transitional cell carcinoma 1 trial · 11 incl. sub-types Sub-types →
- Sarcomatoid transitional cell carcinoma 0 trials · 5 incl. sub-types Sub-types →
- Bartholin gland transitional cell carcinoma 1 trial
- Endometrial transitional cell carcinoma 1 trial
- Primary prostate urothelial carcinoma 0 trials Sub-types →
- Transitional cell carcinoma of the corpus uteri 0 trials
-
Urinary bladder carcinoma 394 trials · 673 incl. sub-types
9 sub-types
- Bladder transitional cell carcinoma 131 trials · 411 incl. sub-types Sub-types →
- Superficial urinary bladder carcinoma 77 trials
- Stage IVb bladder cancer 39 trials
- Urinary bladder small cell neuroendocrine carcinoma 9 trials
- Bladder adenocarcinoma 5 trials · 8 incl. sub-types Sub-types →
- Bladder urachal carcinoma 3 trials · 6 incl. sub-types Sub-types →
- Bladder squamous cell carcinoma 5 trials Sub-types →
- Bladder small cell carcinoma 0 trials
- Childhood bladder carcinoma 0 trials
-
Malignant epithelial tumor of ovary 8 trials · 656 incl. sub-types
6 sub-types
- Ovarian carcinoma 493 trials · 642 incl. sub-types Sub-types →
- Malignant ovarian serous tumor 5 trials · 203 incl. sub-types Sub-types →
- Ovarian endometrial cancer 4 trials · 89 incl. sub-types Sub-types →
- Ovarian clear cell cancer 30 trials · 51 incl. sub-types Sub-types →
- Mucinous ovarian cancer 2 trials · 16 incl. sub-types Sub-types →
- Malignant ovarian Brenner tumor 2 trials
-
Uterine carcinoma 3 trials · 614 incl. sub-types
9 sub-types
- Cervical carcinoma 257 trials · 317 incl. sub-types Sub-types →
- Endometrial carcinoma 209 trials · 316 incl. sub-types Sub-types →
- Endometrial serous adenocarcinoma 36 trials
- Uterus carcinoma in situ 0 trials · 16 incl. sub-types Sub-types →
- Adenoid cystic carcinoma of the corpus uteri 0 trials
- Papillary carcinoma of the corpus uteri 0 trials
- Squamous cell carcinoma of the corpus uteri 0 trials
- Transitional cell carcinoma of the corpus uteri 0 trials
- Undifferentiated carcinoma of the corpus uteri 0 trials
-
Invasive carcinoma 4 trials · 607 incl. sub-types
4 sub-types
- Invasive breast carcinoma 325 trials · 413 incl. sub-types Sub-types →
- Infiltrating urothelial carcinoma 5 trials · 187 incl. sub-types Sub-types →
- Invasive malignant thymoma 4 trials
- Submucosal invasive colon adenocarcinoma 0 trials
-
Peritoneal carcinoma 16 trials · 389 incl. sub-types
3 sub-types
- Primary peritoneal carcinoma 351 trials · 361 incl. sub-types Sub-types →
- Peritoneal serous adenocarcinoma 2 trials · 39 incl. sub-types Sub-types →
- Pseudomyxoma peritonei 17 trials
-
In situ carcinoma 25 trials · 318 incl. sub-types
21 sub-types
- Breast carcinoma in situ 76 trials · 204 incl. sub-types Sub-types →
- Adenocarcinoma in situ 10 trials · 170 incl. sub-types Sub-types →
- Bladder carcinoma in situ 30 trials
- Intestine carcinoma in situ 0 trials · 16 incl. sub-types Sub-types →
- Uterus carcinoma in situ 0 trials · 16 incl. sub-types Sub-types →
- Esophagus carcinoma in situ 13 trials
- Squamous carcinoma in situ 5 trials · 10 incl. sub-types Sub-types →
- Skin carcinoma in situ 3 trials · 9 incl. sub-types Sub-types →
- Oral cavity carcinoma in situ 5 trials Sub-types →
- Stomach carcinoma in situ 4 trials Sub-types →
- Lung carcinoma in situ 2 trials · 3 incl. sub-types Sub-types →
- Pharynx carcinoma in situ 0 trials · 2 incl. sub-types Sub-types →
- Larynx carcinoma in situ 1 trial Sub-types →
- Carcinoma in situ of ureter 0 trials
- Carcinoma in situ of urethra 0 trials
- Eye carcinoma in situ 0 trials
- Gall bladder carcinoma in situ 0 trials
- Grade III prostatic intraepithelial neoplasia 0 trials
- Kidney carcinoma in situ 0 trials Sub-types →
- Liver carcinoma in situ 0 trials Sub-types →
- Nasal cavity carcinoma in situ 0 trials
-
Skin carcinoma 35 trials · 283 incl. sub-types
13 sub-types
- Skin squamous cell carcinoma 151 trials · 158 incl. sub-types Sub-types →
- Cutaneous neuroendocrine carcinoma 78 trials
- Skin basal cell carcinoma 52 trials · 60 incl. sub-types Sub-types →
- Skin carcinoma in situ 3 trials · 9 incl. sub-types Sub-types →
- Anal margin carcinoma 1 trial · 6 incl. sub-types Sub-types →
- Skin appendage carcinoma 4 trials · 6 incl. sub-types Sub-types →
- Eyelid carcinoma 1 trial · 2 incl. sub-types Sub-types →
- Cutaneous Paget disease 0 trials · 1 incl. sub-types Sub-types →
- Borst-Jadassohn intraepidermal carcinoma 0 trials
- Cutaneous mucoepidermoid carcinoma 0 trials
- Labia majora carcinoma 0 trials
- Labia minora carcinoma 0 trials
- Vulvar seborrheic keratosis 0 trials Sub-types →
-
Thyroid gland carcinoma 41 trials · 237 incl. sub-types
11 sub-types
- Differentiated thyroid carcinoma 79 trials · 182 incl. sub-types Sub-types →
- Thyroid gland adenocarcinoma 0 trials · 118 incl. sub-types Sub-types →
- Thyroid gland undifferentiated (anaplastic) carcinoma 35 trials
- Multiple endocrine neoplasia type 2 4 trials · 30 incl. sub-types Sub-types →
- Familial nonmedullary thyroid carcinoma 3 trials · 15 incl. sub-types Sub-types →
- Thyroid gland squamous cell carcinoma 4 trials
- Intrathyroid thymic carcinoma 0 trials
- Thyroid gland cribriform morular carcinoma 0 trials
- Thyroid gland mixed medullary and follicular cell-derived carcinoma 0 trials
- Thyroid gland mucinous carcinoma 0 trials
- Thyroid gland spindle cell tumor with thymus-like differentiation 0 trials
-
Fallopian tube carcinoma 126 trials · 182 incl. sub-types
6 sub-types
- Fallopian tube adenocarcinoma 4 trials · 81 incl. sub-types Sub-types →
- Fallopian tube transitional cell carcinoma 12 trials
- Fallopian tube carcinosarcoma 8 trials
- Fallopian tube gestational choriocarcinoma 0 trials
- Fallopian tube squamous cell carcinoma 0 trials
- Hereditary fallopian tube carcinoma 0 trials
-
Secondary carcinoma 1 trial · 169 incl. sub-types
1 sub-type
- Metastatic carcinoma 22 trials · 168 incl. sub-types Sub-types →
-
Bone carcinoma 0 trials · 131 incl. sub-types
7 sub-types
- Metastatic carcinoma in the bone 107 trials
- Paranasal sinus carcinoma 4 trials · 21 incl. sub-types Sub-types →
- Bone squamous cell carcinoma 0 trials · 11 incl. sub-types Sub-types →
- Pituitary adenocarcinoma 3 trials Sub-types →
- Adamantinoma 0 trials Sub-types →
- Growth hormone-producing pituitary gland carcinoma 0 trials
- Osteosarcoma arising in bone Paget disease 0 trials
-
Basal cell carcinoma 112 trials · 121 incl. sub-types
1 sub-type
- Skin basal cell carcinoma 52 trials · 60 incl. sub-types Sub-types →
-
Laryngeal carcinoma 56 trials · 114 incl. sub-types
8 sub-types
- Laryngeal squamous cell carcinoma 72 trials · 77 incl. sub-types Sub-types →
- Glottis carcinoma 6 trials · 10 incl. sub-types Sub-types →
- Carcinoma of supraglottis 1 trial · 2 incl. sub-types Sub-types →
- Larynx carcinoma in situ 1 trial Sub-types →
- Subglottis carcinoma 1 trial Sub-types →
- Laryngeal adenoid cystic carcinoma 0 trials
- Laryngeal mucoepidermoid carcinoma 0 trials
- Laryngeal small cell carcinoma 0 trials
-
Papillary carcinoma 8 trials · 113 incl. sub-types
5 sub-types
- Papillary adenocarcinoma 2 trials · 93 incl. sub-types Sub-types →
- Papillary transitional cell carcinoma 1 trial · 11 incl. sub-types Sub-types →
- Papillary squamous carcinoma 1 trial · 4 incl. sub-types Sub-types →
- Papillary carcinoma of the cervix uteri 0 trials Sub-types →
- Papillary carcinoma of the corpus uteri 0 trials
-
Large cell carcinoma 2 trials · 87 incl. sub-types
5 sub-types
- Lung large cell carcinoma 11 trials · 37 incl. sub-types Sub-types →
- Thyroid gland undifferentiated (anaplastic) carcinoma 35 trials
- Large cell neuroendocrine carcinoma 12 trials · 31 incl. sub-types Sub-types →
- Nasopharyngeal type undifferentiated carcinoma 2 trials · 3 incl. sub-types Sub-types →
- Salivary gland large cell carcinoma 0 trials
-
Undifferentiated carcinoma 6 trials · 80 incl. sub-types
14 sub-types
- Thyroid gland undifferentiated (anaplastic) carcinoma 35 trials
- Undifferentiated ovarian carcinoma 13 trials
- Endometrial undifferentiated carcinoma 9 trials
- Undifferentiated carcinoma of nasopharynx 7 trials
- Nut midline carcinoma 6 trials
- Sinonasal undifferentiated carcinoma 6 trials
- Undifferentiated carcinoma of esophagus 1 trial
- Undifferentiated carcinoma of liver and intrahepatic biliary tract 1 trial
- Undifferentiated carcinoma of stomach 1 trial
- Undifferentiated pancreatic carcinoma 1 trial Sub-types →
- Salivary gland large cell carcinoma 0 trials
- Thymic undifferentiated carcinoma 0 trials
- Undifferentiated carcinoma of the corpus uteri 0 trials
- Undifferentiated gallbladder carcinoma 0 trials
-
Mucin-producing carcinoma 0 trials · 58 incl. sub-types
2 sub-types
- Mucinous adenocarcinoma 18 trials · 57 incl. sub-types Sub-types →
- Pancreatic mucinous cystadenoma 1 trial
-
Retroperitoneum carcinoma 0 trials · 52 incl. sub-types
1 sub-type
- Adrenal carcinoma 34 trials · 52 incl. sub-types Sub-types →
-
Vulvar carcinoma 24 trials · 45 incl. sub-types
9 sub-types
- Vulvar squamous cell carcinoma 22 trials Sub-types →
- Vulvar adenocarcinoma 3 trials · 5 incl. sub-types Sub-types →
- Bartholin gland carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Clitoral carcinoma 0 trials
- Labia majora carcinoma 0 trials
- Labia minora carcinoma 0 trials
- Vulva basal cell carcinoma 0 trials
- Vulvar neuroendocrine carcinoma 0 trials Sub-types →
- Vulvar seborrheic keratosis 0 trials Sub-types →
-
Thymic carcinoma 41 trials · 44 incl. sub-types
9 sub-types
- Invasive malignant thymoma 4 trials
- Thymic neuroendocrine carcinoma 3 trials Sub-types →
- Lymphoepithelioma-like thymic carcinoma 0 trials
- Malignant type AB thymoma 0 trials
- Thymic sarcomatoid carcinoma 0 trials
- Thymic undifferentiated carcinoma 0 trials
- Thymus clear cell carcinoma 0 trials
- Thymus gland adenocarcinoma 0 trials Sub-types →
- Thymus squamous cell carcinoma 0 trials Sub-types →
-
Penile carcinoma 9 trials · 35 incl. sub-types
3 sub-types
- Squamous cell carcinoma of penis 21 trials · 29 incl. sub-types Sub-types →
- Paget disease of the penis 0 trials
- Penis basal cell carcinoma 0 trials
-
Sarcomatoid carcinoma 1 trial · 26 incl. sub-types
8 sub-types
- Sarcomatoid renal cell carcinoma 15 trials
- Lung sarcomatoid carcinoma 3 trials · 7 incl. sub-types Sub-types →
- Sarcomatoid transitional cell carcinoma 0 trials · 5 incl. sub-types Sub-types →
- Pleomorphic carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Rectal sarcomatoid carcinoma 0 trials
- Sarcomatoid basal cell carcinoma 0 trials
- Sarcomatoid squamous cell carcinoma 0 trials Sub-types →
- Thymic sarcomatoid carcinoma 0 trials
-
Vaginal carcinoma 12 trials · 22 incl. sub-types
2 sub-types
- Vaginal squamous cell carcinoma 8 trials
- Vaginal adenocarcinoma 7 trials Sub-types →
-
Carcinoma of urethra 2 trials · 21 incl. sub-types
5 sub-types
- Urethra transitional cell carcinoma 17 trials Sub-types →
- Urethra adenocarcinoma 1 trial · 2 incl. sub-types Sub-types →
- Urethra squamous cell carcinoma 2 trials Sub-types →
- Littre gland carcinoma 0 trials Sub-types →
- Carcinoma in situ of urethra 0 trials
-
Ureter carcinoma 1 trial · 19 incl. sub-types
6 sub-types
- Ureter transitional cell carcinoma 16 trials Sub-types →
- Ureter adenocarcinoma 1 trial
- Ureter small cell carcinoma 1 trial
- Ureter squamous cell carcinoma 1 trial
- Carcinoma in situ of ureter 0 trials
- Regional ureteric cancer 0 trials
-
Choroid plexus carcinoma 11 trials
1 sub-type
-
Basaloid carcinoma 0 trials · 5 incl. sub-types
2 sub-types
- Basaloid squamous cell carcinoma 2 trials · 5 incl. sub-types Sub-types →
- Basaloid large cell lung carcinoma 0 trials
-
Cribriform carcinoma 1 trial · 4 incl. sub-types
2 sub-types
- Salivary duct carcinoma 3 trials
- Cribriform carcinoma of breast 0 trials Sub-types →
-
Malignant myoepithelioma 2 trials
1 sub-type
- Malignant breast myoepithelioma 0 trials
-
Combined carcinoid and adenocarcinoma 0 trials · 2 incl. sub-types
1 sub-type
- Goblet cell carcinoma 2 trials
-
Carcinoma ex pleomorphic adenoma 1 trial
2 sub-types
-
Trachea carcinoma 1 trial
3 sub-types
- Trachea mucoepidermoid carcinoma 0 trials
- Trachea squamous cell carcinoma 0 trials Sub-types →
- Tracheal adenoid cystic carcinoma 0 trials
-
Scrotal carcinoma 0 trials · 1 incl. sub-types
3 sub-types
- Scrotum squamous cell carcinoma 1 trial
- Scrotum Paget disease 0 trials
- Scrotum basal cell carcinoma 0 trials
-
Krebs 2 carcinoma 0 trials
-
Comedocarcinoma 0 trials
-
Epithelial-myoepithelial carcinoma 0 trials
2 sub-types
-
Glycogen-rich carcinoma 0 trials
1 sub-type
-
Lipid-rich carcinoma 0 trials
1 sub-type
- Lipid-rich breast carcinoma 0 trials
-
Lymph node carcinoma 0 trials
Most studied deeper sub-types
-
Biomarker-Guided combo aims to outsmart tough cancers
Disease control Recruiting nowThis phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
New chemo formula aims to keep lung cancer away after surgery
Disease control Recruiting nowThis study tests a drug called SMS001, a new version of the chemotherapy paclitaxel, in 42 people with non-small cell lung cancer (stages Ib to IIIa). The goal is to see if a single dose after surgery can safely prevent the cancer from coming back. Researchers will monitor side e…
Phase 2 • Sponsor: ToLymph Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for advanced kidney cancer: experimental drug enters human trials
Disease control Recruiting nowThis study tests a new medicine, PF-08634404, in adults with advanced kidney cancer that has spread. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer drugs. About 224 participants who have not had prior treatment for their advanced…
Phase 1/2 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo aims to stop lung cancer return after surgery
Disease control Recruiting nowThis study tests whether adding the drug MK-2870 to standard immunotherapy (pembrolizumab) after surgery can help prevent lung cancer from coming back. It is for people with stage II to IIIB non-small cell lung cancer whose tumor did not fully disappear after chemotherapy and imm…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers: early trial recruits 554 patients
Disease control Recruiting nowThis study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…
Phase 1/2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New lung cancer drug shows promise in early trial
Disease control Recruiting nowThis study tests a new medicine called PF-08634404, given alone or with chemotherapy, for adults with early or locally advanced non-small cell lung cancer. The trial has three parts: before surgery, after surgery if cancer remains, or after chemoradiation. Researchers will check …
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo aims to boost chemoradiation for head and neck cancer
Disease control Recruiting nowThis early-phase study tests whether adding the experimental drug ipatasertib to standard chemotherapy and radiation is safe and effective for people with advanced head and neck cancer. Ipatasertib may help stop cancer cell growth. About 46 participants will receive the combinati…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a gene test guide better treatment for head and neck cancer survivors?
Disease control Recruiting nowThis study compares two treatments after surgery for stage III-IVA head and neck cancer: radiation alone versus radiation plus the chemotherapy drug cisplatin. The goal is to see which approach better prevents the cancer from returning, especially in patients with certain TP53 ge…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New combo therapy aims to stop head and neck cancer from returning
Disease control Recruiting nowThis phase II trial is testing whether adding chemotherapy or chemo-immunotherapy before standard salvage surgery can improve outcomes for patients with PD-L1 positive head and neck cancer that has come back. About 180 participants will receive either carboplatin and paclitaxel, …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug aims to reignite immune attack on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called IL12-L19L19 (Dodekin) in 80 adults with advanced or metastatic solid tumors that have stopped responding to standard immunotherapy. The drug combines an antibody with an immune-boosting protein to target and attack cancer cells.…
Phase 1 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New cancer drug AGX101 enters human trials for advanced tumors
Disease control Recruiting nowThis early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…
Phase 1 • Sponsor: Angiex, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New combo therapy aims to outsmart resistant head and neck cancer
Disease control Recruiting nowThis study tests whether adding cetuximab to standard immunotherapy (pembrolizumab) helps people with advanced head and neck cancer that has stopped responding to platinum chemotherapy live longer. About 158 adults with cancer that has returned or spread will receive either pembr…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a Two-Drug punch before surgery shrink head & neck tumors?
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug AVZO-1418 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 480 adults will take part, receiving the drug alone or with other treatments.
Phase 1/2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Experimental drug plus radiation aims to tackle returning head and neck cancers
Disease control Recruiting nowThis early-phase trial is testing whether a drug called camonsertib, combined with a precise type of radiation, can help control head and neck cancers that have come back or cannot be removed by surgery. About 39 adults with these cancers will receive the drug along with focused …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a platform trial match the right drug combo to each tumor?
Disease control Recruiting nowThis phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…
Phase 1/2 • Sponsor: QuantumLeap Healthcare Collaborative • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New pill shows promise for tough lung cancer mutation
Disease control Recruiting nowThis phase 2b trial tests an oral drug called zipalertinib in 220 people with advanced non-small cell lung cancer that has certain EGFR mutations. The goal is to see if the drug can shrink tumors and how safe it is. Participants take the drug daily, and researchers will monitor t…
Phase 2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for Hard-to-Treat HER2 cancers? early trial launches
Disease control Recruiting nowThis early-phase trial is testing a new drug called DB-1303/BNT323 in people with advanced HER2-positive solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. About 800 participants will take part ac…
Phase 1/2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New hope for liver cancer patients who have no other options
Disease control Recruiting nowThis study is testing a treatment called BSJ019T in Japanese patients with liver cancer that cannot be removed by surgery and has not responded to standard treatments. The goal is to see if the treatment can control the cancer's growth and how safe it is. About 51 participants wi…
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New hope for head and neck cancer: which drug works best with radiation?
Disease control Recruiting nowThis study compares two treatments for people with advanced head and neck cancer who cannot use the standard drug cisplatin. About 454 participants will receive either cetuximab (a targeted antibody) or a chemotherapy combo (carboplatin + paclitaxel) alongside precise radiation t…
Phase 3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New lung cancer combo aims to beat current standard
Disease control Recruiting nowThis study tests whether a new experimental drug called PF-08634404, given with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to rec…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a new immune drug outsmart Hard-to-Treat tumors?
Disease control Recruiting nowThis trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, …
Phase 1/2 • Sponsor: Marengo Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Experimental drug DM005 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called DM005 in 136 people with advanced solid tumors, including lung, head and neck, and other cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and se…
Phase 1/2 • Sponsor: Doma Biopharmaceutical（Suzhou）Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug DM002 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…
Phase 1/2 • Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug PHN-012 takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called PHN-012 in people with advanced colon, pancreatic, or lung cancer that has stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a powerful cancer-killing agent directly to tumor cells…
Phase 1 • Sponsor: Pheon Therapeutics • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Blood test guides safer cancer treatment after surgery
Disease control Recruiting nowThis study tests whether a blood test that detects tumor DNA can help doctors choose the right amount of chemotherapy and radiation after surgery for HPV-positive throat cancer. The goal is to give less intense treatment to patients with a low risk of cancer returning, reducing s…
Phase 2 • Sponsor: Zachary Zumsteg • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug combo aims to fight advanced kidney cancer
Disease control Recruiting nowThis study tests whether a combination of two oral drugs, belzutifan and zanzalintinib, works better than the current standard drug cabozantinib for people with advanced kidney cancer that has come back after prior treatment. About 904 participants will be randomly assigned to on…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can adding radiation boost immunotherapy against spread head and neck cancer?
Disease control Recruiting nowThis trial tests whether adding radiotherapy to the immunotherapy drug pembrolizumab (with or without chemotherapy) helps people with newly diagnosed head and neck cancer that has spread to other parts of the body. Participants receive either standard systemic treatment alone or …
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New antibody combo aims to supercharge immune system against Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goa…
Phase 1/2 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Engineered immune cells target abdominal tumors in colorectal cancer trial
Disease control Recruiting nowThis early-phase trial tests a new treatment for colorectal cancer that has spread to the lining of the abdomen. It combines specially engineered natural killer (NK) cells, given both into a vein and directly into the belly, with the drug cetuximab. The goal is to find the safest…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New drug combo aims to boost lung cancer treatment
Disease control Recruiting nowThis Phase 3 trial tests whether adding Sigvotatug Vedotin to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has high levels of PD-L1. About 714 participants will receive either the combinati…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a Two-Drug cocktail keep bladder cancer from coming back?
Disease control Recruiting nowThis phase 3 trial is testing whether a combination of two drugs—datopotamab deruxtecan and rilvegostomig—given after surgery can prevent cancer recurrence in people with high-risk muscle invasive bladder cancer. Participants who have had their tumor completely removed will recei…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New combo therapy aims to shrink rectal tumors before surgery
Disease control Recruiting nowThis phase 2 trial will test whether adding immunotherapy drugs (cemiplimab alone or with fianlimab or REGN7075) to standard chemotherapy (capecitabine and oxaliplatin) can completely eliminate tumors in patients with locally advanced rectal cancer before surgery. The study plans…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New pill shows promise against tough cancers in early trial
Disease control Recruiting nowThis study tests a new oral drug called NXP900 in people with advanced solid tumors (like lung, kidney, or mesothelioma) that have not responded to standard treatments. The trial has two parts: first, finding the right dose, and then seeing if the drug shrinks tumors. It is a fir…
Phase 1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Lung cancer Patients' own immune cells could shrink tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests a personalized therapy called LN-145, made from a patient's own tumor-fighting immune cells. Researchers take a sample of the tumor, grow the immune cells in a lab, and then infuse them back into the patient after a short course of chemotherapy. The goal …
Phase 2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Lab-Grown mini tumors could guide pancreatic cancer treatment
Disease control Recruiting nowThis study explores whether growing miniature versions of a patient's own pancreatic tumor in the lab (called organoids) can help doctors choose the most effective drug for that individual. About 25 adults with advanced, inoperable pancreatic cancer will have their tumor organoid…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could a simple ointment replace surgery for some skin cancers?
Disease control Recruiting nowThis study tests whether an ointment called tirbanubulin can effectively treat superficial basal cell carcinoma, a common type of skin cancer. Adults with small, previously untreated lesions on the body (not the face or scalp) apply the ointment once daily for five days. If the l…
Phase 2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take on Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis phase 1 trial tests a new therapy called MSK-TCR5 for people with advanced solid tumors that have a specific genetic change (RAS G12D mutation) and a certain immune type (HLA-A*11:01). The therapy uses a patient's own T-cells, modified in a lab to better recognize and attack…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug BAL0891 enters human trials for Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…
Phase 1 • Sponsor: SillaJen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene-Hacked immune cells take on tough cancers
Disease control Recruiting nowThis study tests a new treatment called IOV-4001 for people with advanced melanoma or non-small-cell lung cancer. The treatment uses a patient's own tumor-fighting immune cells, which are collected, genetically modified to remove a 'brake' called PD-1, and then infused back after…
Phase 1/2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New pill targets KRAS cancers in early human trial
Disease control Recruiting nowThis early-phase trial tests an oral drug called ALTA3263 in about 448 adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a KRAS mutation. The main goals are to check safety, find the right dose, and see how the body processes the drug. Part…
Phase 1 • Sponsor: Alterome Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Cancer-Fighting virus plus chemo and immunotherapy takes on lung cancer in new trial
Disease control Recruiting nowThis study tests a new approach for people with advanced lung cancer whose disease got worse after initial treatment. It combines an injected virus (Olvi-Vec) that targets cancer cells, followed by chemotherapy and an immunotherapy drug, and compares it to standard chemotherapy a…
Phase 2 • Sponsor: Genelux Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could a simple injection treat leg skin cancer?
Disease control Recruiting nowThis early-stage trial tests injecting a chemotherapy drug (5FU) directly into skin cancers on the lower legs, with or without a vitamin D-based cream (calcipotriene). The goal is to see if the treatment is safe and can shrink tumors. About 30 adults with small squamous cell carc…
Phase 1 • Sponsor: Melissa Pugliano-Mauro • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New targeted drug shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called repotrectinib in people with advanced solid tumors that have certain gene changes (ALK, ROS1, or NTRK). The trial has two parts: first, finding a safe dose, and second, seeing how well the drug shrinks tumors. About 500 adults with advanced canc…
Phase 1/2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for stomach cancer patients with abdominal spread
Disease control Recruiting nowThis study tests whether the chemotherapy drug paclitaxel, given before and after stomach removal surgery, can improve outcomes for people with gastric cancer that has spread to the lining of the abdomen. About 30 adults with this condition will receive the drug and be monitored …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Engineered immune cells take aim at childhood cancers
Disease control Recruiting nowThis early-stage trial tests a new immunotherapy for children and young adults up to age 21 with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein…
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for EGFR lung cancer: Dato-DXd combo tested in phase 3 trial
Disease control Recruiting nowThis Phase 3 trial is testing whether the drug Dato-DXd, given alone or with osimertinib, can help people with a specific type of advanced lung cancer (EGFR-mutated) that has stopped responding to osimertinib. About 744 participants will be randomly assigned to receive either the…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Pill combo offers new hope for rural head and neck cancer patients
Disease control Recruiting nowThis study is testing whether taking three oral chemotherapy drugs together is safe and practical for patients with head and neck cancer that has returned or spread. The trial focuses on people living in rural Midwest areas, making it easier for them to participate from home. The…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Blood test could help throat cancer patients get less radiation
Disease control Recruiting nowThis phase II trial tests whether a blood test that detects HPV DNA can help doctors decide the right amount of radiation for people with HPV-positive throat cancer. About 455 participants will either have surgery or receive standard chemotherapy plus radiation, but the radiation…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New antibody drug aims to unleash immune system on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug, UCB4594, in people with advanced solid tumors that haven't responded to standard treatments. The drug is a monoclonal antibody that targets a protein called HLA-G on cancer cells, potentially helping the immune system attack them. The stud…
Phase 1/2 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Experimental vaccine combo aims to supercharge immune attack on bile duct cancer
Disease control Recruiting nowThis early-phase study tests a personalized peptide vaccine (mBTCvax) combined with two immunotherapy drugs (durvalumab and tremelimumab) in 25 adults with advanced biliary tract cancer. The goal is to see if the combination is safe and can boost the immune system's ability to ta…
Phase 1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New immunotherapy combo may let older colorectal cancer patients skip surgery
Disease control Recruiting nowThis study tests whether immunotherapy drugs (cemiplimab alone or with fianlimab) can shrink or eliminate tumors in older patients (70+) or those unfit for surgery with a specific genetic type of colorectal cancer (MSI-H). The goal is to avoid surgery if the cancer disappears com…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New cocktail aims to tackle tough pancreatic cancer
Disease control Recruiting nowThis phase 2 trial tests a new drug called NC410 combined with standard chemotherapy (FOLFIRINOX) and immunotherapy drugs (nivolumab with or without ipilimumab) in 20 people with metastatic pancreatic cancer who have not had prior treatment. The main goal is to check safety and i…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo aims to tackle tough uterine cancer
Disease control Recruiting nowThis study tests a combination of two drugs, cabozantinib and dostarlimab, in 37 women with recurrent gynecologic carcinosarcoma, a rare and aggressive cancer. The goal is to see if the combo can keep the cancer from growing for at least 6 months. Participants must have had at le…
Phase 1/2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New Two-Part cancer drug enters first human tests
Disease control Recruiting nowThis early-stage trial is testing a new drug called TGW101 in people with advanced solid tumors that have not responded to other treatments. TGW101 is given in two parts: an antibody-drug conjugate and a chemical trigger that activates it. The main goal is to check safety and fin…
Phase 1 • Sponsor: Tagworks Pharmaceuticals BV • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called INV-1120, either by itself or combined with the immunotherapy pembrolizumab (Keytruda), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses an…
Phase 1 • Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Heated chemo plus targeted drug shows promise in ovarian cancer trial
Disease control Recruiting nowThis study tests a new approach for advanced ovarian cancer. Patients take a targeted drug (olaparib) for a week before surgery, then receive heated chemotherapy directly in the abdomen during the operation. The goal is to see if this combination is safe and effective. The trial …
Phase 1/2 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Personalized vaccine takes on head and neck cancer in early trial
Disease control Recruiting nowThis early-phase trial tests a personalized vaccine made from a patient's own tumor cells, given alone or with the immunotherapy drug pembrolizumab, for people with head and neck cancer that has returned or spread. The main goals are to check safety, find the best dose, and see i…
Phase 1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Timing is everything: new trial tests best duration of hormone therapy before breast cancer surgery
Disease control Recruiting nowThis study looks at how long hormone-blocking therapy given before surgery (neoadjuvant endocrine therapy) affects breast cancer in people with early-stage disease. About 90 participants will receive therapy for different lengths of time, from weeks up to a year. Researchers want…
Phase 2 • Sponsor: George Washington University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Can a common cholesterol drug boost immunotherapy against head and neck cancer?
Disease control Recruiting nowThis phase II trial tests whether adding lovastatin, a common cholesterol-lowering drug, to the immunotherapy pembrolizumab can help shrink tumors in people with head and neck cancer that has returned or spread. The study will enroll 28 adults whose tumors express PD-L1. Research…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug combo aims to shrink lung tumors enough for surgery
Disease control Recruiting nowThis phase II trial tests whether a new drug called IBI363, combined with standard chemotherapy, can shrink stage III non-small cell lung cancer that was initially too advanced to remove with surgery. The goal is to make the tumors operable, then remove them. About 43 adults with…
Phase 2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for rare liver cancer: drug duo targets tumor fuel
Disease control Recruiting nowThis study tests whether combining a glutamine-blocking drug (DRP-104) with an immunotherapy (durvalumab) can shrink or control advanced fibrolamellar carcinoma, a rare liver cancer. About 27 people aged 12 and older whose cancer has worsened despite prior treatment will receive …
Phase 1/2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug targets hard-to-treat KRAS cancers in early trial
Disease control Recruiting nowThis study tests a new drug called WEF-001 in people with advanced solid tumors that have a KRAS mutation, including pancreatic, colorectal, and lung cancers. The goal is to check the drug's safety and how well it shrinks tumors. About 110 adults who have already tried standard t…
Phase 1/2 • Sponsor: Auricula Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New pill plus chemo shows promise for tough head and neck cancers
Disease control Recruiting nowThis phase 2 trial is testing an oral drug called NRC-2694-A combined with the chemotherapy paclitaxel in people with recurrent or metastatic head and neck squamous cell carcinoma that has worsened after immunotherapy. About 21 adults will receive the combination to see if it shr…
Phase 2 • Sponsor: NATCO Pharma Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New cancer drug MT-4561 enters first human tests
Disease control Recruiting nowThis early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…
Phase 1/2 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for kidney cancer: Real-World study tests vorolanib as Second-Line therapy
Disease control Recruiting nowThis study looks at how well the drug vorolanib works for people with advanced kidney cancer that cannot be removed by surgery or has spread. It is for patients who need a second treatment after their first one stopped working. The study will track how long the cancer stays under…
Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New drug combo aims to shrink bile duct tumors before surgery
Disease control Recruiting nowThis study tests whether giving a mix of two chemotherapy drugs (gemcitabine and cisplatin) plus an immunotherapy drug (pembrolizumab) before and after surgery is safe and helps shrink tumors in people with biliary tract cancer. About 27 adults with resectable cancer will take pa…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Poop pills plus immunotherapy: new hope for stubborn cancers?
Disease control Recruiting nowThis study tests whether a fecal microbiota transplant (FMT) combined with the immunotherapy drug nivolumab can help people with advanced solid cancers that stopped responding to prior treatment. About 50 participants will receive the combination to see if it can shrink tumors. T…
Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New vaccine combo aims to boost immune attack on pancreatic cancer
Disease control Recruiting nowThis study tests two different cancer vaccines (GVAX and a KRAS peptide vaccine) given with two immunotherapy drugs (balstilimab and AGEN2373) in people with pancreatic cancer that can be surgically removed. The goal is to find the safest dose and see if the combination helps the…
Phase 1/2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New particle beam therapy targets stubborn liver tumors
Disease control Recruiting nowThis study tests a precise type of radiation called carbon ion radiotherapy for people with liver cancer that remains or comes back after a prior treatment (TARE). About 48 adults will receive this targeted radiation, with doctors tracking how well it shrinks tumors and whether s…
Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New combo therapy aims to boost liver cancer treatment
Disease control Recruiting nowThis study tests whether adding a precise type of radiation (carbon ion radiotherapy) to standard immunotherapy drugs (atezolizumab and bevacizumab) can better control advanced liver cancer. About 52 adults with liver cancer that cannot be surgically removed will receive this com…
Phase 2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Can a tracer that hunts unstable iron light up hidden tumors?
Diagnosis Recruiting nowThis phase 1 trial is testing whether a new imaging tracer called 18F-TRX can safely and effectively detect solid tumors using PET scans. The tracer targets unstable iron levels, which are often elevated in cancerous tissue. Adults with advanced solid tumors, including certain pr…
Phase 1 • Sponsor: Rahul Aggarwal • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
Can a simple ultrasound spot liver cancer treatment success faster?
Diagnosis Recruiting nowThis study tests whether contrast-enhanced ultrasound (CEUS) can better detect if liver cancer (HCC) has been killed by radioembolization treatment. Standard CT or MRI scans often take months to show clear results, delaying further treatment. Researchers will enroll 30 patients a…
Phase 2 • Sponsor: Thomas Jefferson University • Aim: Diagnosis
Last updated Jun 27, 2026 13:05 UTC
-
New imaging agent could spot multiple cancers with one scan
Diagnosis Recruiting nowThis study is testing a new type of PET scan that uses special radioactive tracers to find and map solid tumors in the body. The tracers target a protein called Trop2, which is often found on cancer cells. Researchers will enroll 400 people with various cancers (including bladder…
Phase 2/3 • Sponsor: RenJi Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New radiotracer aims to spot hidden cancers
Diagnosis Recruiting nowThis study tests a new radioactive tracer called [68Ga]Ga-PN-EpC1 for PET/CT scans in 30 people with suspected or confirmed epithelial tumors. The tracer targets a protein called EpCAM found on many cancer cells. Researchers want to see if it can find tumors more accurately than …
Sponsor: Peking University People's Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:03 UTC
-
New drug aims to ease painful mouth sores for head and neck cancer patients
Symptom relief Recruiting nowThis phase II trial tests whether adding BMX-001 to standard symptom management can reduce severe mouth sores in head and neck cancer patients receiving chemoradiation. About 98 participants will receive either BMX-001 or a placebo alongside usual care. The goal is to see if BMX-…
Phase 2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
-
Antidepressant may ease brain fog from lung cancer drug
Symptom relief Recruiting nowThis study tests whether vortioxetine, an antidepressant known to boost thinking skills, can reduce the mental fogginess caused by the lung cancer drug lorlatinib. About 24 adults with advanced ALK-positive lung cancer who are already taking lorlatinib will receive vortioxetine. …
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New lattice radiation aims to shrink bulky tumors and ease pain
Symptom relief Recruiting nowThis study tests a special type of radiation called lattice therapy for people with large, hard-to-treat tumors. The goal is to see if it can shrink tumors better than standard radiation and help people feel better. About 37 adults with advanced solid tumors will receive this tre…
Phase 2 • Sponsor: University of Cincinnati • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Which cancer care model boosts quality of life? large trial seeks answers
Symptom relief Recruiting nowThis study compares two approaches to supportive cancer care for nearly 3,000 adults with cancer. One group gets information through email or their health record, while the other works one-on-one with a lay health worker over 12 months. The goal is to see which model better impro…
Sponsor: Stanford University • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Scientists hunt for hidden genes behind hereditary cancers
Knowledge-focused Recruiting nowThis study collects tissue samples, medical data, and family histories from over 1,100 people being screened for colorectal or endometrial cancer. Researchers hope to discover new genes and mechanisms that increase cancer risk, especially in hereditary cancer syndromes. The goal …
Sponsor: Weill Medical College of Cornell University • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Remote hearing tests could save cancer Patients' hearing
Knowledge-focused Recruiting nowThis study tests whether offering hearing tests close to home or remotely increases how many head and neck cancer patients get their hearing checked during treatment. Many patients on cisplatin chemotherapy or radiation near the ear can lose hearing, but not all complete recommen…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
New tool helps nasal cancer patients voice their satisfaction
Knowledge-focused Recruiting nowThis study aims to validate a French version of the Nasal Reconstruction FACE-Q questionnaire, which measures how patients feel about their appearance, quality of life, and side effects after nasal reconstruction or prosthetic rehabilitation following nasal skin cancer surgery. A…
Sponsor: Hôpital NOVO • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Lynch syndrome study seeks to uncover hidden skin cancer link
Knowledge-focused Recruiting nowThis study aims to find out how often Muir-Torre syndrome (MTS) occurs in people who already have Lynch syndrome, a genetic condition that raises cancer risk. Researchers will examine skin lesions and tumors from 150 participants to see if they are linked to MTS. The goal is to b…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Rare sinus cancer study aims to clarify treatment outcomes
Knowledge-focused Recruiting nowThis study follows people with a rare and advanced cancer of the nasal cavity and sinuses called T4 sinonasal adenoid cystic carcinoma. All participants receive the standard treatment: surgery followed by radiation therapy. The goal is to measure how long people live without the …
Sponsor: Eye & ENT Hospital of Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New PET tracer could light up tumors for better cancer imaging
Knowledge-focused Recruiting nowThis early-phase study tests a new radioactive tracer called [89Zr]DFO-starPEG to see if it can make tumors show up better on PET scans. The goal is to learn how the tracer behaves in the body and whether it can help doctors see the "leakiness" of tumor blood vessels, which may g…
Phase 1 • Sponsor: Robert Flavell, MD, PhD • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
PET scans may reveal early if immunotherapy works for lung cancer
Knowledge-focused Recruiting nowThis study is testing whether special PET scans can predict early on if immunotherapy (with or without chemotherapy) is working in people with advanced non-small cell lung cancer. Researchers will scan 200 patients before treatment, then at 6 and 12 weeks, looking for signs that …
Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Gut bacteria may boost cancer immunotherapy: new trial launches
Knowledge-focused Recruiting nowThis study looks at how gut bacteria affect immunotherapy in people with advanced solid tumors. It has two parts: first, finding bacterial markers linked to treatment response; second, testing if fecal transplants from healthy donors can make immunotherapy work better. About 60 a…
Sponsor: Asan Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Simple test for throat cancer on the horizon?
Knowledge-focused Recruiting nowThis study from Mayo Clinic aims to find biological markers (biomarkers) in blood, tissue, and saliva that can signal the presence or absence of HPV-related oropharyngeal cancer. Researchers will follow 560 participants, including patients with and without the disease, to see if …
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Can blood tests predict who will do their swallowing exercises?
Knowledge-focused Recruiting nowThis study looks at why people with head and neck cancer follow (or don't follow) swallowing exercises after radiation. Researchers will use blood tests and questionnaires to see if immune system proteins or feelings about the disease affect exercise habits. The goal is to find w…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
1,500 patients to fuel pancreatic cancer research
Knowledge-focused Recruiting nowThis study collects tumor tissue and medical information from 1,500 people with pancreatic cancer. The goal is to build a large biobank that scientists can use to better understand the disease and develop new treatments. Participants undergo standard diagnostic procedures, and no…
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Simple blood test may predict deadly clots in cancer patients
Knowledge-focused Recruiting nowThis study is testing whether a monthly blood test can predict dangerous blood clots in people with certain cancers (lung, pancreatic, stomach, or brain). Cancer patients are at high risk for clots, which can be deadly. Researchers will follow 200 participants for 12 months, taki…
Sponsor: Institut Cancerologie de l'Ouest • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Blood tests could predict cancer therapy success
Knowledge-focused Recruiting nowThis study looks for proteins and other markers in the blood of 2000 adults with or suspected of having cancer. The goal is to find markers that may help doctors confirm a cancer diagnosis, choose the right treatment, and predict how well a patient will respond or if the cancer w…
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
New cancer registry aims to unlock secrets of ovarian and endometrial cancer treatment
Knowledge-focused Recruiting nowThis study is a large German registry that will follow nearly 2,000 people with advanced ovarian or endometrial cancer. Researchers will collect information on the treatments patients actually receive, how their disease responds, and their quality of life. The goal is to understa…
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Mini-Tumors in a dish could predict best cancer therapy
Knowledge-focused Recruiting nowThis study is testing whether tiny lab-grown copies of a patient's tumor, called organoids, can help predict which cancer treatment will work best. Researchers will collect tumor and blood samples from 20 people with undifferentiated carcinoma before they start standard therapy. …
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Blood test may spot kidney cancer return before scans do
Knowledge-focused Recruiting nowThis study looks at whether a simple blood test that finds bits of tumor DNA can help doctors monitor kidney cancer after surgery. Researchers will follow 450 people who have just been diagnosed with kidney cancer and are having surgery to remove it. The goal is to see if the blo…
Sponsor: Jinling Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
AI aims to revolutionize cancer trial enrollment for 50,000 patients
Knowledge-focused Recruiting nowThis study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to…
Sponsor: Massive Bio, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
New imaging study aims to spot radiation damage to neck arteries
Knowledge-focused Recruiting nowThis study looks at how radiation therapy for head and neck cancers affects the blood vessels in the neck. Researchers will use two types of PET/CT scans to compare images taken before and after treatment. The goal is to better understand and detect radiation-related vascular dam…
Early phase 1 • Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC